Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02442986
Other study ID # URostock
Secondary ID
Status Completed
Phase N/A
First received April 29, 2015
Last updated April 19, 2017
Start date November 2012
Est. completion date March 2017

Study information

Verified date April 2017
Source University of Rostock
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Systemic inflammation and sepsis cause multi organ failure including severe neurologic impairment in the course of disease. Neurologic failure typically presents as critical-illness-polyneuropathy/-myopathy and septic encephalopathy during sepsis and is associated with an increased mortality rate.

Clinical parameters to determine the neurologic entities during the course of sepsis are heterogeneous. Further research for an association of clinical parameters and the patients' outcome is needed.

The study aims toward differences in the clinical and neurological outcome of surgical and non-surgical septic patients in comparison to non-septic patients on ICU. The aim of the study is to identify clinical and diagnostic outcome predictors in septic patients.


Description:

All patients with severe sepsis and septic shock and fulfilling the inclusion criteria should be screened for the study on two surgical (septic surgical patients), one medical intensive care unit (septic non-surgical patients) and one neurological intensive care unit (non-septic patients) at the university hospital of Rostock, Germany.

The inclusion of patients will be started if written informed consent was obtained from all participants or their representatives (if direct consent could not be obtained).

The aim of the study is to determine differences in the neurological outcome of surgical and non-surgical septic patients (incidence, severity and length of critical-illness-polyneuropathy/-myopathy and septic encephalopathy). The main interest of the study is to find parameters associated with an improved neurological outcome in septic patients within an observation time of 100 days.

The main criterion is the incidence, severity and length of septic encephalopathy and critical-illness-polyneuropathy and -myopathy on days 7 and 28.

From all patients basic demographic data, illness severity scores (APACHE-II, SOFA) and delirium scores for the assessment of septic encephalopathy (CAM-ICU, ICDSC), laboratory, cerebrospinal fluid and microbiological results, electrophysiological (electroneurography(ENG)), electroencephalography (EEG), cranial MRI results, pre-morbidity data and clinical outcome for the study cohort will be recorded. At the days 1, 3, 7 and 28 the patients will be screened for clinical and laboratory/immunological data: hemodynamic, inflammation, coagulation, organ function, blood parameters including cytokines.

Neurological examination and EEG will be performed within 24 hours after the beginning of the study. Examination of liquor cerebrospinalis will be performed within 24-48 hours and cranial MRI between day 3 and 7 after the inclusion of the patient. ENG will be done earliest one week after the beginning of the study.


Recruitment information / eligibility

Status Completed
Enrollment 32
Est. completion date March 2017
Est. primary completion date March 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Fulfilling criteria for severe sepsis or septic shock

Exclusion Criteria:

- Diagnosis of cerebrovascular disease (pre-existing)

- Advanced dementia

- Diagnosis of pre-existing other neuromuscular disease

- High-dose glucocorticosteroid therapy (> 300 mg Hydrocortisone/die)

- Pre-existing renal replacement therapy

- Coagulation disorder with bleeding

- Frequent administration of neuromuscular blocking agents (> 3 times/week)

Study Design


Locations

Country Name City State
Germany Intensive Care Units PIT 1+2, University hospital Rostock Rostock

Sponsors (1)

Lead Sponsor Collaborator
University of Rostock

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Septic Encephalopathy EEG, MRT, CSF (cerebrospinal fluid) day 7
Primary Critical-Illness-Polyneuropathy and -myopathy ENG day 7
Primary Septic Encephalopathy (28) Clinical observation. day 28
Primary Critical-Illness-Polyneuropathy and -myopathy (28) Clinical observation. day 28
Secondary - 28-day survival (observation time 100 days) Survival after 28 days. day 28
Secondary - Time of respirator-therapy In days cumulative. 1 year
Secondary - Dosage of vasopressors (cumulative) In days cumulative. observation time 100 days
Secondary - 100 day survival Survival after 100 days. day 100
See also
  Status Clinical Trial Phase
Recruiting NCT06374719 - WiTNNess - TNNT1 Myopathy Natural History Study
Not yet recruiting NCT03633565 - Comparative Study of Strategies for Management of Duchenne Myopathy (DM) Phase 4
Enrolling by invitation NCT02235220 - Reduction of Masticatory Muscle Activity by Restoring Canine Guidance N/A
Terminated NCT00278564 - Stem Cell Transplantation in Idiopathic Inflammatory Myopathy Diseases Phase 1
Completed NCT01642056 - EPI-743 for Metabolism or Mitochondrial Disorders Phase 1/Phase 2
Completed NCT02011282 - Electro-Neuro-Muscular Stimulation in ICU N/A
Completed NCT01702987 - Evaluation of Ubiquinol on Mitochondrial Oxidative Capacity in Statin Patients Using 31PMRS N/A
Active, not recruiting NCT01225614 - Efficacy and Tolerance of Early Launching of Nocturnal Non Invasive Phase 3
Recruiting NCT03749538 - Acute Transcranial Direct Current Stimulation in Patients With Systemic Autoimmune Myopathies N/A
Recruiting NCT01022450 - Study of the Causes of the Breakdown of Muscle Fibers in Hospitalized Patients N/A
Withdrawn NCT00990834 - Muscle Characteristics Associated With Statin Therapy N/A
Active, not recruiting NCT00937001 - Critical Illness Myopathy as a Cause of Debilitating ICU-Acquired Weakness N/A
Recruiting NCT01353430 - Characterization of Inclusion Body Myopathy Associated With Paget's Disease of Bone and Frontotemporal Dementia (IBMPFD)
Completed NCT03751644 - Peripherical Neuromuscular Electrical Stimulation in Systemic Autoimmune Myopathies N/A
Completed NCT02765828 - Identification of Tongue Involvement in Late-Onset Pompe Disease
Recruiting NCT05599568 - Repeated Bout Effect i Neuromuscular Diseases N/A
Withdrawn NCT02124070 - Therapeutic Effect of Recombinant Human Growth Hormone (rhGH) on the Myopathy of Cystinosis Phase 1/Phase 2
Completed NCT02706314 - Impact of Human Blood Serum From Critically Ill Patients on Human Colon Neuronal Networks.
Recruiting NCT03042286 - SAPhIRE Statin Adverse Drug Reaction
Not yet recruiting NCT04941079 - Safety and Efficacy of Inactivated SARS-CoV-2 Vaccine in Immune-related Myopathy (Myasthenia Gravis and Inflammatory Myopathy) Patients :a Prospective Observational Study